


Wide spectrum AMP to treat veterinary infections




Temporine-SHa derived peptide from *Pelophylax saharica*

CMI results in μM

Strain	Lead T2	Ref ATB
<i>E. coli</i> ATCC 8739	12.5	
<i>S. aureus</i> ATCC 6538	3.5	
<i>S. aureus</i> ATCC 19636	<1.5 6	0.7 ^c
<i>S. aureus</i> BAA-1717 (MRSA)	3.12	0.35 ^c
<i>S. aureus</i> BAA-1556 (MRSA)	3.12	0.7 ^c
<i>P. aeruginosa</i> ATCC15692	>75	0.25 ^b
<i>C. albicans</i> ATCC 44858	37.5	0.125 ^a

a : Amphotericin B
b : Ciprofloxacin
c : Vancomycin

MOA : rapid membranolytic effect which make it difficult for the pathogen to develop resistance



A Few Numbers

Veterinary Drug Market value is about 28 Billion Euro,

French market

- 859 Million Euro, about 3% World Market.

- 6 700 Workers

- 3000 AMM

Therapeutics

- Antibacterial

- Alternative

- Peptides



SUGGESTED APPLICATIONS

Topical treatment for skin diseases caused by bacterial, yeasts or parasites infections



DEVELOPMENT STATUS

In vivo proof-of-concept has been done with SHa original peptide on leishmania.

After a *hit-to-lead* phase in order to optimize peptide activity, SATT Lutec is funding a development program to have an *in vivo* proof-of-concept with our *lead* peptide. Considering it has **specific efficiency against MR staphylococci strains**, we want to test it on a recognized **pyodermitis** model.

We are looking for industrial partners with strong expertise in the field, in order to co-develop the technology, get advises on animal model and the best conditions to assess.



INNOVATIVE SOLUTION

Teams from Sorbonne University and IRD discovered new natural peptides that exhibit wide antimicrobial properties to treat skin diseases.

Those peptides were extracted from amphibians' skin and analyzed to select actives peptides and create optimized AMPs.




SORBONNE
UNIVERSITÉ



COMPETITIVE ADVANTAGES

- Curative treatment for skin diseases caused by bacterial or yeasts infections
- Broad spectrum AMP with increased efficiency **against staphylococci pathogens, responsible for Pyodermitis**
- Can be combined with classic systemic antibiotics to improve their action
- **Rapid acting** peptides (less than 15 min), allowing reduction of treatment duration



Quick and low-production costs (13



AA) IP RIGHTS

Priority patent application filled in 2013 for new peptides.

Currently granted application in EP, US and JP.

